Roy C C, Weber A M, Morin C L, Combes J C, Nusslé D, Mégevand A, Lasalle R
N Engl J Med. 1977 Dec 15;297(24):1301-5. doi: 10.1056/NEJM197712152972401.
Because of the increased incidence of gallstones in cystic fibrosis we compared biliary lipid composition in 26 patients with cystic fibrosis, seven children with cholelithiasis but no cystic-fibrosis and 13 controls. Eighteen of the cystic fibrosis group had cholecystograms, and only one had gallstones. In 14 patients with cystic fibrosis who had stopped taking pancreatic enzymes for one week molar percentage of lipid composition accounted for by cholesterol (mean +/- S.E., 16.3 +/- 2.9) and saturation index (2.0 +/- 0.3) were comparable to values of the cholelithiasis group and higher (P less than 0.01) than those of controls. In 12 patients with cystic fibrosis taking pancreatic enzymes, molar percentage of cholesterol (8.6 +/- 1.7) and saturation index (1.0 +/- 0.1) did not differ from those of controls; in cystic fibrosis there was a preponderance of cholic over chenodeoxycholic acid both off (1.7 +/- 0.2) and on (1.9 +/- 0.3) therapy as compared to the cholelithiasis (0.7 +/- 0.1) and control (0.8 +/- 0.0) groups. The glycine/taurine ratio of conjugated bile acids were lower in enzyme-treated patients with cystic fibrosis (3.7 +/- 0.6) than in patients off treatment (6.4 +/- 1.0), but was higher (P less than 0.01) than in controls (1.8 +/- 0.2). Bile is lithogenic in untreated cystic fibrosis and responds to pancreatic enzymes.
由于囊性纤维化患者胆结石发病率增加,我们比较了26例囊性纤维化患者、7例患有胆石症但无囊性纤维化的儿童以及13名对照者的胆汁脂质成分。囊性纤维化组中有18例进行了胆囊造影,只有1例有胆结石。在14例已停用胰酶一周的囊性纤维化患者中,胆固醇占脂质成分的摩尔百分比(均值±标准误,16.3±2.9)和饱和指数(2.0±0.3)与胆石症组的值相当,且高于(P<0.01)对照组。在12例服用胰酶的囊性纤维化患者中,胆固醇的摩尔百分比(8.6±1.7)和饱和指数(1.0±0.1)与对照组无差异;与胆石症组(0.7±0.1)和对照组(0.8±0.0)相比,囊性纤维化患者在未接受治疗(1.7±0.2)和接受治疗(1.9±0.3)时,胆酸与鹅去氧胆酸的比例均较高。接受酶治疗的囊性纤维化患者结合胆汁酸的甘氨酸/牛磺酸比值(3.7±0.6)低于未接受治疗的患者(6.4±1.0),但高于(P<0.01)对照组(1.8±0.2)。未治疗的囊性纤维化患者的胆汁具有致石性,且对胰酶有反应。